作者: Vahideh Ahmadzadeh , Roghaye Tofigh , Safar Farajnia , Nasser Pouladi
DOI: 10.3109/08830185.2015.1077830
关键词: Tumor microenvironment 、 Immunotherapy 、 Antibody 、 Leukemia 、 B cell 、 Lymphoma 、 Immunology 、 Medicine 、 Pathogenesis 、 Cancer research 、 Crosstalk (biology)
摘要: Most B-cell-related disorders can be cured with conventional agents; however, relapse is common, creating a need for additional therapeutic options. In agreement, recent biomarker studies corroborate the role played by functional crosstalk between malignant B cells and microenvironment which have added texture to clinical outcome. Here we outline essential of tumor-associated niche in B-cell Lymphoma/Leukemia pathogenesis, an attempt optimize use microenvironment-targeted drugs anti-CD20 antibodies various subsets.